First-in-Human Study of STX-478, a Mutant Selective PI3K alpha Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Primary Objective

This is a first-in-human study to learn more about the investigational drug STX-478. The study will have 3 parts.

Is This Study For You?

Let's Get Started!

Description

Part 1 will study STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will study STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Anthony Elias

Anthony Elias

Study ID

Protocol Number: 23-0200

More information available at ClinicalTrials.gov: NCT05768139

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers